Adicet Bio, Inc. announced that updated safety and efficacy data from the Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL) will be delivered as an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and online June 3-7, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.56 USD | +4.70% | -3.11% | -17.46% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.46% | 128M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+36.70% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- ACET Stock
- News Adicet Bio, Inc.
- Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting